-
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
-
FCM MM Holdings Condemns ISS Report on Mind Medicine (MNMD)
-
ISS Appears to Rely on MindMed's False and Misleading Statements to Justify the Company's Abysmal Performance; Seemingly Ignores MindMed's Apparent Disregard of Patient Safety
-
FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board
-
FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed
-
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
-
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track
-
FCM Releases Letter to Fellow MindMed Shareholders Highlighting Board and Management’s Track Record of Shareholder Value Destruction
-
FCM Nominates Exceptional Director Candidates to Restore MindMed’s Value
-
FCM Nominates Exceptional Director Candidates to Restore MindMed’s Value
-
Activist Investor Accuses Mind Medicine (MNMD) of Financial Misstatements, Questions Internal Controls
-
Activist Investor Informs MindMed of Financial Misstatements, Questions Internal Controls
-
Activist Investor Informs MindMed of Financial Misstatements, Questions Internal Controls
-
Significant MindMed Investor Demands Federal Investigation to Probe Serious Allegations of Misconduct
-
Significant MindMed Investor Demands Federal Investigation to Probe Serious Allegations of Misconduct
-
Mind Medicine (MNMD) Announces Appointment of Dr. Sarah Y. Vinson as Additional Director
-
MindMed Announces Appointment of Dr. Sarah Y. Vinson as Additional Director

